...
首页> 外文期刊>Laboratory investigation >Secretory leukocyte protease inhibitor gene deletion alters bleomycin-induced lung injury, but not development of pulmonary fibrosis
【24h】

Secretory leukocyte protease inhibitor gene deletion alters bleomycin-induced lung injury, but not development of pulmonary fibrosis

机译:分泌型白细胞蛋白酶抑制剂基因缺失改变博来霉素诱导的肺损伤,但不改变肺纤维化的发展

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Idiopathic pulmonary fibrosis is a progressive, fatal disease with limited treatment options. Protease-mediated transforming growth factor-β (TGF-β) activation has been proposed as a pathogenic mechanism of lung fibrosis. Protease activity in the lung is tightly regulated by protease inhibitors, particularly secretory leukocyte protease inhibitor (SLPI). The bleomycin model of lung fibrosis was used to determine the effect of increased protease activity in the lungs of Slpi?/? mice following injury. Slpi?/?, and wild-type, mice received oropharyngeal administration of bleomycin (30?IU) and the development of pulmonary fibrosis was assessed. Pro and active forms of matrix metalloproteinase (MMP)-2 and MMP-9 were measured. Lung fibrosis was determined by collagen subtype-specific gene expression, hydroxyproline concentration, and histological assessment. Alveolar TGF-β activation was measured using bronchoalveolar lavage cell pSmad2 levels and global TGF-β activity was assessed by pSmad2 immunohistochemistry. The active-MMP-9 to pro-MMP-9 ratio was significantly increased in Slpi?/? animals compared with wild-type animals, demonstrating enhanced metalloproteinase activity. Wild-type animals showed an increase in TGF-β activation following bleomycin, with a progressive and sustained increase in collagen type I, alpha 1 (Col1α1), III, alpha 1(Col3α1), IV, alpha 1(Col4α1) mRNA expression, and a significant increase in total lung collagen 28 days post bleomycin. In contrast Slpi?/? mice showed no significant increase of alveolar TGF-β activity following bleomycin, above their already elevated levels, although global TGF-β activity did increase. Slpi?/? mice had impaired collagen gene expression but animals demonstrated minimal reduction in lung fibrosis compared with wild-type animals. These data suggest that enhanced proteolysis does not further enhance TGF-β activation, and inhibits sustained Col1α1, Col3α1, and Col4α1 gene expression following lung injury. However, these changes do not prevent the development of lung fibrosis. Overall, these data suggest that the absence of Slpi does not markedly modify the development of lung fibrosis following bleomycin-induced lung injury.
机译:特发性肺纤维化是一种进行性致命疾病,治疗选择有限。蛋白酶介导的转化生长因子-β(TGF-β)激活被认为是肺纤维化的致病机制。肺部蛋白酶活性受蛋白酶抑制剂,尤其是分泌型白细胞蛋白酶抑制剂(SLPI)的严格调控。肺纤维化博来霉素模型被用于确定增加的蛋白酶活性在Slpiβ/β肺中的作用。小鼠受伤后。 Slpi /β和野生型小鼠接受口咽给予博来霉素(30μIU),并评估了肺纤维化的发展。测量了基质金属蛋白酶(MMP)-2和MMP-9的前体和活性形式。肺纤维化由胶原亚型特异性基因表达,羟脯氨酸浓度和组织学评估确定。使用支气管肺泡灌洗细胞pSmad2水平测量肺泡TGF-β活化,并通过pSmad2免疫组织化学评估整体TGF-β活性。活性MMP-9与pro-MMP-9之比在Slpiβ/β中显着增加。与野生型动物相比,这表明金属蛋白酶活性增强。野生型动物显示出博来霉素后TGF-β活化增加,并且胶原I,α1(Col1α1),III,α1(Col3α1),IV,α1(Col4α1)mRNA表达持续不断增加,博莱霉素治疗28天后总肺胶原显着增加。相反,Slpi?/?博莱霉素治疗后的小鼠肺泡TGF-β活性没有显着增加,高于已经升高的水平,尽管总体TGF-β活性确实增加了。 Slpi?/?小鼠的胶原蛋白基因表达受损,但与野生型动物相比,动物的肺纤维化减少最小。这些数据表明增强的蛋白水解作用不会进一步增强TGF-β的激活,并抑制肺损伤后持续的Col1α1,Col3α1和Col4α1基因表达。但是,这些变化不会阻止肺纤维化的发展。总体而言,这些数据表明,Slpi的缺乏并不能明显改变博来霉素诱导的肺损伤后肺纤维化的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号